Advertisement

Journal of Inherited Metabolic Disease

, Volume 24, Supplement 2, pp 97–105 | Cite as

Clinically relevant therapeutic endpoints in type I Gaucher disease

  • C. E. M. Hollak
  • M. Maas
  • J. M. Aerts
Article

Abstract

The introduction of enzyme supplementation therapy for Gaucherdisease has had a great impact on the lives of many patients. Organomegaly, cytopenia and bone disease have been shown to improve in response to treatment, resulting in an improvement in quality of life. However, the assessment of organ system involvement is not always done in such a way that the relationship with clinically relevant endpoints is clear. The lack of adequately validated methods of assessment, especially for bone disease, has hindered the establishment of treatment goals and guidelines for treatment optimization.

Keywords

Enzyme Replacement Therapy Gauche Disease Liver Volume Enzyme Therapy Gauche Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Aerts JM, Hollak CE (1997) Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 10: 691–709.PubMedGoogle Scholar
  2. Barton NW, Brady RO, Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464–1470.PubMedCrossRefGoogle Scholar
  3. Beutler E, Demina A, Laubscher K, et al (1995) The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis 21: 86–108.PubMedCrossRefGoogle Scholar
  4. Beutler E, Grabowski G (1995) Gaucher disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th edn. New York: McGraw-Hill Publishing Company.Google Scholar
  5. Boot RG, Renkema GH, Verhoek M, et al (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273: 25680–25685.PubMedCrossRefGoogle Scholar
  6. Charrow J, Andersson HC, Kaplan P, et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835–2843.PubMedCrossRefGoogle Scholar
  7. Charrow J, Esplin JA, Gribble TJ, et al (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158: 1754–1760.PubMedCrossRefGoogle Scholar
  8. Colburn WA (2000) Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J Clin Pharmacol 40(12 Pt 2): 1419–1427.PubMedGoogle Scholar
  9. Cox TM, Schofield JP (1997) Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 10: 657–689.PubMedGoogle Scholar
  10. Cummings SR, Black DM, Nevitt MC, et al (1993) Bone density at various sites for prediction of hip fractures. Lancet 341: 72–75.PubMedCrossRefGoogle Scholar
  11. Damiano AM, Pastores GM, Ware JE Jr (1998) The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 7: 373–386.PubMedCrossRefGoogle Scholar
  12. Ek M, Guijt M, Oosterveld P, Hollak CEM (1999) Quality of life in patients with Gaucher disease in the Netherlands. Abstract, 3rd Meeting of the European Working Group on Gaucher Disease, Lemnos: 18.Google Scholar
  13. Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A (1996) Effect of lowdose ERT on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 22: 104–111.PubMedCrossRefGoogle Scholar
  14. Figueroa ML, Rosenbloom BE, Kay AC, et al (1992) A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 327: 1632–1636.PubMedCrossRefGoogle Scholar
  15. Grabowski GA (1996). Current issues in enzyme therapy for Gaucher disease. Drugs 52: 159–167.PubMedCrossRefGoogle Scholar
  16. Gielchinsky Y, Elstein D, Hadas-Halpern I, Lahad A, Abrahamov A, Zimran A (1999) Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease. Br J Haematol 106: 812–816.PubMedCrossRefGoogle Scholar
  17. Hollak CE, Aerts JM, Goudsmit R, et al (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345: 1474–1478.PubMedCrossRefGoogle Scholar
  18. Hollak CE, Corssmit EP, Aerts JM, et al (1997a) Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. Am J Med 103: 185–191.PubMedCrossRefGoogle Scholar
  19. Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH (1997b) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96: 470–476.PubMedCrossRefGoogle Scholar
  20. Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93: 1288–1292.PubMedCrossRefGoogle Scholar
  21. Johnson LA, Hoppel BE, Gerard EL, et al (1992) Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 182: 451–455.PubMedGoogle Scholar
  22. Maas M, Akkerman EM, Hollak CEM, et al (1999) Radiological, biochemical and clinical parameters of skeletal disease in relation to fat fraction determination by QCSI in type 1 Gaucher disease. Abstract, 3rd Meeting of the European Working Group on Gaucher Disease, Lemnos: 40.Google Scholar
  23. Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK (1999) Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 8: 263–268.PubMedCrossRefGoogle Scholar
  24. Miller SP, Zirzow GC, Doppelt SH, Brady RO, Barton NW (1996). Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med 127: 353–358.PubMedCrossRefGoogle Scholar
  25. NIH Technology Assessment Panel on Gaucher Disease (1996) Current issues in diagnosis and treatment. JAMA 275: 548–553.CrossRefGoogle Scholar
  26. Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82: 408–416.PubMedGoogle Scholar
  27. Rodrigue SW, Rosenthal DI, Barton NW, Zurakowski D, Mankin HJ (1999) Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin Orthop 362: 201–207.PubMedCrossRefGoogle Scholar
  28. Rose JS, Grabowski GA, Barnett SH, Desnick RJ (1982) Accelerated skeletal deterioration after splenectomy in Gaucher type 1 disease. AJR Am J Roentgenol 139: 1202–1204.PubMedGoogle Scholar
  29. Rosenthal DI, Doppelt SH, Mankin HJ, et al (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629–637.PubMedGoogle Scholar
  30. Van Weely S, Hollak CE, Maas M, Boot RG, Aerts JM (1999) Determination of plasma chitotriosidase in Gaucher disease: practical implications. Abstract, 3rd Meeting of the European Working Group on Gaucher Disease, Lemnos: 71.Google Scholar
  31. Zimran A, Elstein D, Kannai R, et al (1994). Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 97: 3–13.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • C. E. M. Hollak
    • 1
  • M. Maas
    • 1
  • J. M. Aerts
    • 1
  1. 1.Department of Hematology F4-224Academic Medical CenterAmsterdamThe Netherlands

Personalised recommendations